Dr. Reddy’s Moves Quick On First Generic Allegra-D 12 Hour Extended Release
This article was originally published in The Tan Sheet
Executive Summary
Generics of fexofenadine-only Allegra and fexofenadine/pseudoephedrine Allegra-D 24 Hour launched soon after the branded product’s switch in 2011, Dr. Reddy’s abbreviated NDA for a generic of Allegra-D 12 Hour Allergy & Congestion is the first approved by FDA.
You may also be interested in...
With OTC Cialis Rights, Sanofi Launches Latest Salvo In Consumer Sector Battle
Sanofi gains rights from Eli Lilly & Co. to apply for OTC approval of Cialis in the U.S., Europe, Canada and Australia. Launching the first OTC product indicated for erectile dysfunction would mark another milestone in Sanofi CEO Chris Viebacher’s mission to move the firm into the neighborhood of global OTC leaders.
Dr. Reddy’s Projects 50% Growth In U.S. OTC Business
The Indian private labeler predicts annualized U.S. OTC sales of $200 million by March 2013. Dr. Reddy’s recently launched an equivalent of Allegra-D 24 Hour and plans to introduce generic Prevacid 24HR in its next fiscal year.
Martek/Mead Agreement
Martek BioSciences will be the exclusive, worldwide supplier of DHA (docosahexaenoic acid) and ARA (arachidonic acid) to infant formula company Mead Johnson (Enfamil) according to a ten-year supply agreement, the firm announces May 18. The agreement is an expansion and extension of a 25-year license agreement signed in 1992. Martek's blend is the only source of these nutrients currently used in U.S. infant formula. However, Abbott Lab's Ross Products Division's (Similac) tuna oil-derived DHA and fungally-derived ARA was granted Generally Recognized as Safe status for use in infant formula by FDA May 18. Martek does not expect to lose customers to Ross because of the latter's GRAS status, the firm asserts in a same-day release. "The levels of DHA and ARA specified in the notification are significantly lower than levels used in the majority of all term and pre-term infant formula sold in the U.S.," Martek notes...